The global market for Age-related Macular Degeneration was estimated to be worth US$ 7725.7 million in 2023 and is forecast to a readjusted size of US$ 11400 million by 2030 with a CAGR of 5.8% during the forecast period 2024-2030

Age-related Macular Degeneration - Market

North American market for Age-related Macular Degeneration was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Age-related Macular Degeneration was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Europe market for Age-related Macular Degeneration was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global key companies of Age-related Macular Degeneration include Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb and Gilead Sciences, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Age-related Macular Degeneration, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Age-related Macular Degeneration by region & country, by Type, and by Application.

The Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-related Macular Degeneration.

Market Segmentation

Scope of Age-related Macular Degeneration - Market Report

Report Metric	Details
Report Name	Age-related Macular Degeneration - Market
Forecasted market size in 2030	US$ 11400 million
CAGR	5.8%
Forecasted years	2024 - 2030
Segment by Type:	Wet AMD Dry AMD
Segment by Application	Drugstore Hospital Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb, Gilead Sciences, Iconic Therapeutics, Neurotech Pharmaceuticals, Ohr Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Age-related Macular Degeneration manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Age-related Macular Degeneration in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Age-related Macular Degeneration in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Age-related Macular Degeneration - Market size in 2030?

Ans: The Age-related Macular Degeneration - Market size in 2030 will be US$ 11400 million.

Who are the main players in the Age-related Macular Degeneration - Market report?

Ans: The main players in the Age-related Macular Degeneration - Market are Bayer HealthCare, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, Alcon, Allergan, Avalanche, Bausch+Lomb, Gilead Sciences, Iconic Therapeutics, Neurotech Pharmaceuticals, Ohr Pharmaceutical

What are the Application segmentation covered in the Age-related Macular Degeneration - Market report?

Ans: The Applications covered in the Age-related Macular Degeneration - Market report are Drugstore, Hospital, Others

What are the Type segmentation covered in the Age-related Macular Degeneration - Market report?

Ans: The Types covered in the Age-related Macular Degeneration - Market report are Wet AMD, Dry AMD

1 Market Overview

1.1 Age-related Macular Degeneration Product Introduction

1.2 Global Age-related Macular Degeneration Market Size Forecast

1.3 Age-related Macular Degeneration Market Trends & Drivers

1.3.1 Age-related Macular Degeneration Industry Trends

1.3.2 Age-related Macular Degeneration Market Drivers & Opportunity

1.3.3 Age-related Macular Degeneration Market Challenges

1.3.4 Age-related Macular Degeneration Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Age-related Macular Degeneration Players Revenue Ranking (2023)

2.2 Global Age-related Macular Degeneration Revenue by Company (2019-2024)

2.3 Key Companies Age-related Macular Degeneration Manufacturing Base Distribution and Headquarters

2.4 Key Companies Age-related Macular Degeneration Product Offered

2.5 Key Companies Time to Begin Mass Production of Age-related Macular Degeneration

2.6 Age-related Macular Degeneration Market Competitive Analysis

2.6.1 Age-related Macular Degeneration Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Age-related Macular Degeneration Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-related Macular Degeneration as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Wet AMD

3.1.2 Dry AMD

3.2 Global Age-related Macular Degeneration Sales Value by Type

3.2.1 Global Age-related Macular Degeneration Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Age-related Macular Degeneration Sales Value, by Type (2019-2030)

3.2.3 Global Age-related Macular Degeneration Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Drugstore

4.1.2 Hospital

4.1.3 Others

4.2 Global Age-related Macular Degeneration Sales Value by Application

4.2.1 Global Age-related Macular Degeneration Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Age-related Macular Degeneration Sales Value, by Application (2019-2030)

4.2.3 Global Age-related Macular Degeneration Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Age-related Macular Degeneration Sales Value by Region

5.1.1 Global Age-related Macular Degeneration Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Age-related Macular Degeneration Sales Value by Region (2019-2024)

5.1.3 Global Age-related Macular Degeneration Sales Value by Region (2025-2030)

5.1.4 Global Age-related Macular Degeneration Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Age-related Macular Degeneration Sales Value, 2019-2030

5.2.2 North America Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Age-related Macular Degeneration Sales Value, 2019-2030

5.3.2 Europe Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Age-related Macular Degeneration Sales Value, 2019-2030

5.4.2 Asia Pacific Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Age-related Macular Degeneration Sales Value, 2019-2030

5.5.2 South America Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Age-related Macular Degeneration Sales Value, 2019-2030

5.6.2 Middle East & Africa Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Age-related Macular Degeneration Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Age-related Macular Degeneration Sales Value

6.3 United States

6.3.1 United States Age-related Macular Degeneration Sales Value, 2019-2030

6.3.2 United States Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Age-related Macular Degeneration Sales Value, 2019-2030

6.4.2 Europe Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Age-related Macular Degeneration Sales Value, 2019-2030

6.5.2 China Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.5.3 China Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Age-related Macular Degeneration Sales Value, 2019-2030

6.6.2 Japan Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Age-related Macular Degeneration Sales Value, 2019-2030

6.7.2 South Korea Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Age-related Macular Degeneration Sales Value, 2019-2030

6.8.2 Southeast Asia Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Age-related Macular Degeneration Sales Value, 2019-2030

6.9.2 India Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

6.9.3 India Age-related Macular Degeneration Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Bayer HealthCare

7.1.1 Bayer HealthCare Profile

7.1.2 Bayer HealthCare Main Business

7.1.3 Bayer HealthCare Age-related Macular Degeneration Products, Services and Solutions

7.1.4 Bayer HealthCare Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.1.5 Bayer HealthCare Recent Developments

7.2 F. Hoffmann-La Roche

7.2.1 F. Hoffmann-La Roche Profile

7.2.2 F. Hoffmann-La Roche Main Business

7.2.3 F. Hoffmann-La Roche Age-related Macular Degeneration Products, Services and Solutions

7.2.4 F. Hoffmann-La Roche Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.2.5 F. Hoffmann-La Roche Recent Developments

7.3 Novartis

7.3.1 Novartis Profile

7.3.2 Novartis Main Business

7.3.3 Novartis Age-related Macular Degeneration Products, Services and Solutions

7.3.4 Novartis Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.3.5 Regeneron Pharmaceuticals Recent Developments

7.4 Regeneron Pharmaceuticals

7.4.1 Regeneron Pharmaceuticals Profile

7.4.2 Regeneron Pharmaceuticals Main Business

7.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Products, Services and Solutions

7.4.4 Regeneron Pharmaceuticals Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.4.5 Regeneron Pharmaceuticals Recent Developments

7.5 Alcon

7.5.1 Alcon Profile

7.5.2 Alcon Main Business

7.5.3 Alcon Age-related Macular Degeneration Products, Services and Solutions

7.5.4 Alcon Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.5.5 Alcon Recent Developments

7.6 Allergan

7.6.1 Allergan Profile

7.6.2 Allergan Main Business

7.6.3 Allergan Age-related Macular Degeneration Products, Services and Solutions

7.6.4 Allergan Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.6.5 Allergan Recent Developments

7.7 Avalanche

7.7.1 Avalanche Profile

7.7.2 Avalanche Main Business

7.7.3 Avalanche Age-related Macular Degeneration Products, Services and Solutions

7.7.4 Avalanche Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.7.5 Avalanche Recent Developments

7.8 Bausch+Lomb

7.8.1 Bausch+Lomb Profile

7.8.2 Bausch+Lomb Main Business

7.8.3 Bausch+Lomb Age-related Macular Degeneration Products, Services and Solutions

7.8.4 Bausch+Lomb Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.8.5 Bausch+Lomb Recent Developments

7.9 Gilead Sciences

7.9.1 Gilead Sciences Profile

7.9.2 Gilead Sciences Main Business

7.9.3 Gilead Sciences Age-related Macular Degeneration Products, Services and Solutions

7.9.4 Gilead Sciences Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.9.5 Gilead Sciences Recent Developments

7.10 Iconic Therapeutics

7.10.1 Iconic Therapeutics Profile

7.10.2 Iconic Therapeutics Main Business

7.10.3 Iconic Therapeutics Age-related Macular Degeneration Products, Services and Solutions

7.10.4 Iconic Therapeutics Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.10.5 Iconic Therapeutics Recent Developments

7.11 Neurotech Pharmaceuticals

7.11.1 Neurotech Pharmaceuticals Profile

7.11.2 Neurotech Pharmaceuticals Main Business

7.11.3 Neurotech Pharmaceuticals Age-related Macular Degeneration Products, Services and Solutions

7.11.4 Neurotech Pharmaceuticals Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.11.5 Neurotech Pharmaceuticals Recent Developments

7.12 Ohr Pharmaceutical

7.12.1 Ohr Pharmaceutical Profile

7.12.2 Ohr Pharmaceutical Main Business

7.12.3 Ohr Pharmaceutical Age-related Macular Degeneration Products, Services and Solutions

7.12.4 Ohr Pharmaceutical Age-related Macular Degeneration Revenue (US$ Million) & (2019-2024)

7.12.5 Ohr Pharmaceutical Recent Developments

8 Industry Chain Analysis

8.1 Age-related Macular Degeneration Industrial Chain

8.2 Age-related Macular Degeneration Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Age-related Macular Degeneration Sales Model

8.5.2 Sales Channel

8.5.3 Age-related Macular Degeneration Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Bayer HealthCare

F.Hoffmann-La Roche

Novartis

Regeneron Pharmaceuticals

Neurotech Pharmaceuticals

Ohr Pharmaceutical

Allergan plc

Avalanche

List of Tables

Table 1. Age-related Macular Degeneration Market Trends

Table 2. Age-related Macular Degeneration Market Drivers & Opportunity

Table 3. Age-related Macular Degeneration Market Challenges

Table 4. Age-related Macular Degeneration Market Restraints

Table 5. Global Age-related Macular Degeneration Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Age-related Macular Degeneration Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Age-related Macular Degeneration Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Age-related Macular Degeneration Product Type

Table 9. Key Companies Time to Begin Mass Production of Age-related Macular Degeneration

Table 10. Global Age-related Macular Degeneration Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-related Macular Degeneration as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Age-related Macular Degeneration Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Age-related Macular Degeneration Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Age-related Macular Degeneration Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Age-related Macular Degeneration Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Age-related Macular Degeneration Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Age-related Macular Degeneration Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Age-related Macular Degeneration Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Age-related Macular Degeneration Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Age-related Macular Degeneration Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Age-related Macular Degeneration Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Age-related Macular Degeneration Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Age-related Macular Degeneration Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Age-related Macular Degeneration Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Age-related Macular Degeneration Sales Value by Region (2019-2024) & (%)

Table 27. Global Age-related Macular Degeneration Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Age-related Macular Degeneration Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Age-related Macular Degeneration Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Age-related Macular Degeneration Sales Value, (2025-2030) & (US$ Million)

Table 31. Bayer HealthCare Basic Information List

Table 32. Bayer HealthCare Description and Business Overview

Table 33. Bayer HealthCare Age-related Macular Degeneration Products, Services and Solutions

Table 34. Revenue (US$ Million) in Age-related Macular Degeneration Business of Bayer HealthCare (2019-2024)

Table 35. Bayer HealthCare Recent Developments

Table 36. F. Hoffmann-La Roche Basic Information List

Table 37. F. Hoffmann-La Roche Description and Business Overview

Table 38. F. Hoffmann-La Roche Age-related Macular Degeneration Products, Services and Solutions

Table 39. Revenue (US$ Million) in Age-related Macular Degeneration Business of F. Hoffmann-La Roche (2019-2024)

Table 40. F. Hoffmann-La Roche Recent Developments

Table 41. Novartis Basic Information List

Table 42. Novartis Description and Business Overview

Table 43. Novartis Age-related Macular Degeneration Products, Services and Solutions

Table 44. Revenue (US$ Million) in Age-related Macular Degeneration Business of Novartis (2019-2024)

Table 45. Novartis Recent Developments

Table 46. Regeneron Pharmaceuticals Basic Information List

Table 47. Regeneron Pharmaceuticals Description and Business Overview

Table 48. Regeneron Pharmaceuticals Age-related Macular Degeneration Products, Services and Solutions

Table 49. Revenue (US$ Million) in Age-related Macular Degeneration Business of Regeneron Pharmaceuticals (2019-2024)

Table 50. Regeneron Pharmaceuticals Recent Developments

Table 51. Alcon Basic Information List

Table 52. Alcon Description and Business Overview

Table 53. Alcon Age-related Macular Degeneration Products, Services and Solutions

Table 54. Revenue (US$ Million) in Age-related Macular Degeneration Business of Alcon (2019-2024)

Table 55. Alcon Recent Developments

Table 56. Allergan Basic Information List

Table 57. Allergan Description and Business Overview

Table 58. Allergan Age-related Macular Degeneration Products, Services and Solutions

Table 59. Revenue (US$ Million) in Age-related Macular Degeneration Business of Allergan (2019-2024)

Table 60. Allergan Recent Developments

Table 61. Avalanche Basic Information List

Table 62. Avalanche Description and Business Overview

Table 63. Avalanche Age-related Macular Degeneration Products, Services and Solutions

Table 64. Revenue (US$ Million) in Age-related Macular Degeneration Business of Avalanche (2019-2024)

Table 65. Avalanche Recent Developments

Table 66. Bausch+Lomb Basic Information List

Table 67. Bausch+Lomb Description and Business Overview

Table 68. Bausch+Lomb Age-related Macular Degeneration Products, Services and Solutions

Table 69. Revenue (US$ Million) in Age-related Macular Degeneration Business of Bausch+Lomb (2019-2024)

Table 70. Bausch+Lomb Recent Developments

Table 71. Gilead Sciences Basic Information List

Table 72. Gilead Sciences Description and Business Overview

Table 73. Gilead Sciences Age-related Macular Degeneration Products, Services and Solutions

Table 74. Revenue (US$ Million) in Age-related Macular Degeneration Business of Gilead Sciences (2019-2024)

Table 75. Gilead Sciences Recent Developments

Table 76. Iconic Therapeutics Basic Information List

Table 77. Iconic Therapeutics Description and Business Overview

Table 78. Iconic Therapeutics Age-related Macular Degeneration Products, Services and Solutions

Table 79. Revenue (US$ Million) in Age-related Macular Degeneration Business of Iconic Therapeutics (2019-2024)

Table 80. Iconic Therapeutics Recent Developments

Table 81. Neurotech Pharmaceuticals Basic Information List

Table 82. Neurotech Pharmaceuticals Description and Business Overview

Table 83. Neurotech Pharmaceuticals Age-related Macular Degeneration Products, Services and Solutions

Table 84. Revenue (US$ Million) in Age-related Macular Degeneration Business of Neurotech Pharmaceuticals (2019-2024)

Table 85. Neurotech Pharmaceuticals Recent Developments

Table 86. Ohr Pharmaceutical Basic Information List

Table 87. Ohr Pharmaceutical Description and Business Overview

Table 88. Ohr Pharmaceutical Age-related Macular Degeneration Products, Services and Solutions

Table 89. Revenue (US$ Million) in Age-related Macular Degeneration Business of Ohr Pharmaceutical (2019-2024)

Table 90. Ohr Pharmaceutical Recent Developments

Table 91. Key Raw Materials Lists

Table 92. Raw Materials Key Suppliers Lists

Table 93. Age-related Macular Degeneration Downstream Customers

Table 94. Age-related Macular Degeneration Distributors List

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Age-related Macular Degeneration Product Picture

Figure 2. Global Age-related Macular Degeneration Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Age-related Macular Degeneration Sales Value (2019-2030) & (US$ Million)

Figure 4. Age-related Macular Degeneration Report Years Considered

Figure 5. Global Age-related Macular Degeneration Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Age-related Macular Degeneration Revenue in 2023

Figure 7. Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Wet AMD Picture

Figure 9. Dry AMD Picture

Figure 10. Global Age-related Macular Degeneration Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Age-related Macular Degeneration Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Drugstore

Figure 13. Product Picture of Hospital

Figure 14. Product Picture of Others

Figure 15. Global Age-related Macular Degeneration Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Age-related Macular Degeneration Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Age-related Macular Degeneration Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Age-related Macular Degeneration Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Age-related Macular Degeneration Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Age-related Macular Degeneration Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Age-related Macular Degeneration Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Age-related Macular Degeneration Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Age-related Macular Degeneration Sales Value (%), (2019-2030)

Figure 28. United States Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 34. China Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 36. China Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 46. India Age-related Macular Degeneration Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Age-related Macular Degeneration Sales Value by Type (%), 2023 VS 2030

Figure 48. India Age-related Macular Degeneration Sales Value by Application (%), 2023 VS 2030

Figure 49. Age-related Macular Degeneration Industrial Chain

Figure 50. Age-related Macular Degeneration Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions